Alelion Q2: Short Term Challenges - Redeye

Redeye considers Alelion’s Q2’22 report on the weak side as some orders were pushed into the future, even so, sales growth amounted to 36% y/y. Most noteworthy is the strained financial position, as we expect current funds to cover operations for about two quarters.

Länk till analysen i sin helhet: https://www.redeye.se/research/851747/alelion-q222-short-term-challenges?utm_source=finwire&utm_medium=RSS